No article text was recorded for this version.
correlates of protection
Version 2 of 263 papers82 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Evaluating Immune Correlates in HIV Type 1 Vaccine Efficacy Trials: What RV144 May Provide
- Blog: Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
- Blog: Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
- Blog: The quest for vaccine-induced immune correlates of protection against tuberculosis
- Blog: Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data
- Blog: P-2051. Assessing SARS-CoV-2 Correlates Protection from Exposed Household Members: A Prospective Cohort Study (AB-PROTECT Study)
- Blog: HIV-1 Superinfection Occurs Less Frequently Than Initial Infection in a Cohort of High-Risk Kenyan Women
- Blog: Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection
- Blog: Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial
- Blog: The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
- Blog: Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone
- Blog: P19-57 LB. Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys
- Blog: Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses
- Blog: Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
- Blog: Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide.
- Blog: Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals
- Blog: Acute and persistent responses after H5N1 vaccination in humans
- Blog: Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
- Blog: Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
- Blog: Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America
- Blog: Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
- Blog: Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial
- Blog: Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
- Blog: Development of a novel-ionizable-lipid-based mRNA vaccine for broad protection against Streptococcus pneumoniae
- Blog: Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
- Blog: AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
- Blog: A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice
- Blog: Exploring the standardized detection and sampling methods of human nasal SARS-CoV-2 RBD IgA
- Blog: Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1
- Blog: Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine
- Blog: SWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses
- Blog: Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2
- Blog: Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as the primary mechanism of vaccine-induced protection against HIV-1
- Blog: Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial
- Blog: Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
- Blog: Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
- Blog: Correlation analysis of the total IgY level in hen serum, egg yolk and offspring serum
- Blog: A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity
- Blog: Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
- Blog: Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
- Blog: Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape over Time
- Blog: Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom
- Blog: The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom
- Blog: Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
- Blog: Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial
- Blog: Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
- Blog: Endpoints and Regulatory Issues in HIV Vaccine Clinical Trials
- Blog: Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
- Blog: Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells
- Blog: Designing a Study of Correlates of Risk for Ebola Vaccination
- Blog: Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
- Blog: Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial
- Blog: A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
- Blog: ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost
- Blog: Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine
- Blog: Statistical evaluation of HIV vaccines in early clinical trials
- Blog: Evidence for antibody as a protective correlate for COVID-19 vaccines
- Blog: Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
- Blog: RNA-seq liver transcriptome analysis reveals an activated MHC-I pathway and an inhibited MHC-II pathway at the early stage of vaccine immunization in zebrafish
- Blog: Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy
Showing 60 of 63 papers.
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_correlates_of_protection_57edb01d,
title = {correlates of protection},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/correlates-of-protection/rdr_57edb01d8b7748e7901592bd905c4032},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 2, frozen text):
@misc{lacuna_correlates_of_protection_57edb01d_v2,
title = {correlates of protection},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/correlates-of-protection/rdr_57edb01d8b7748e7901592bd905c4032/v/2},
note = {Version 2, frozen 2026-10-04. Accessed 2026-11-19},
}